{"id":"dab56ad9-ac24-5b50-8705-1d157471a09d","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-areds-longterm","predicate":"associated_with_lower","statement":"Ten-year analysis by original L+Z assignment gave late-AMD HR 0.91 (95% CI 0.84–0.99).","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"6924f284-9378-5364-a6a3-f3ca5de0a8cd","mechanism_event_label":"A modest long-term association favored original assignment.","subject":{"id":"23b4e9a5-0e3d-578b-aff7-100c6a8ac3e7","slug":"areds2-lz-addition","display_name":"AREDS2 lutein/zeaxanthin addition to background AREDS formulation","entity_type_key":"chemical_species"},"object":{"id":"39040b3b-1179-517e-8047-d32ae991ad03","slug":"human-late-amd-progression","display_name":"Progression to late age-related macular degeneration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"6924f284-9378-5364-a6a3-f3ca5de0a8cd","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-areds-longterm-event","event_type":"observed_intervention","label":"A modest long-term association favored original assignment.","description":"Ten-year analysis by original L+Z assignment gave late-AMD HR 0.91 (95% CI 0.84–0.99).","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5dd84367-3f8e-5a3f-b952-a96174ea51fa","slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"},"role":"combination_component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"0a60c685-7502-5ece-9da2-2c1a2e3bcdf1","slug":"zeaxanthin","display_name":"Dietary (3R,3-prime-R)-zeaxanthin","entity_type_key":"small_molecule"},"role":"combination_component","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"23b4e9a5-0e3d-578b-aff7-100c6a8ac3e7","slug":"areds2-lz-addition","display_name":"AREDS2 lutein/zeaxanthin addition to background AREDS formulation","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"39040b3b-1179-517e-8047-d32ae991ad03","slug":"human-late-amd-progression","display_name":"Progression to late age-related macular degeneration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/lutein-research/35653117.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb\", \"start_char\": 0, \"end_char\": 3155, \"text_sha256\": \"66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Ten-year epidemiologic follow-up of randomized AREDS2 assignments","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Original randomization followed by common AREDS2 supplementation for everyone","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not ten years of continuously separated randomized treatment; same cohort, additional follow-up.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Lutein research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"3882 original participants","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A modest long-term association favored original assignment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Late AMD and lung cancer","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"404d7a78-a074-5852-929e-5edb603eddfa","evidence_kind":"source_excerpt","locator":"Lines 788-799","start_line":788,"end_line":799,"excerpt":"### lutein-areds-longterm\nTen-year analysis by original L+Z assignment gave late-AMD HR 0.91 (95% CI 0.84–0.99).\nCondition category: normal\nnutrient_topic: Lutein research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A modest long-term association favored original assignment.\norganism: 3882 original participants\ntissue_or_cell_type: Late AMD and lung cancer\nexperimental_model: Ten-year epidemiologic follow-up of randomized AREDS2 assignments\nlimitations: Not ten years of continuously separated randomized treatment; same cohort, additional follow-up.\nexposure: Original randomization followed by common AREDS2 supplementation for everyone\nevidence_span: {\"source_cache\": \"artifacts/lutein-research/35653117.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb\", \"start_char\": 0, \"end_char\": 3155, \"text_sha256\": \"66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb\"}\n[lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640","model_system":"Ten-year epidemiologic follow-up of randomized AREDS2 assignments","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"beef4241-6ebd-5b36-864c-6ef3ed7e61b8","stable_key":"import-cfa4bd86-d88d-555a-975c-68877bf00e0f","title":"Lutein: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"1514ec459913a7044b4c4e1012ed367bcb918298181ebabd2a9e2ccecd789053","revision_id":"bae2c856-0785-546f-b08f-869318c27f9e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}